Q1 2025 Holdings
Filed 2025-05-15 | 62 holdings | $313.7M | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Roivant Sciences LTD(ROIV) | SHS | G76279101 | $26.0M | 2,578,860 | 8.3% |
| Syndax Pharmaceuticals Inc(SNDX) | COM | 87164F105 | $19.6M | 1,598,594 | 6.3% |
| Scholar Rock Hldg Corp(SRRK) | COM | 80706P103 | $18.2M | 566,212 | 5.8% |
| Arcellx Inc(ACLX) | COMMON STOCK | 03940C100 | $18.0M | 273,774 | 5.7% |
| Merus N V | COM | N5749R100 | $14.6M | 346,756 | 4.7% |
| Immunovant Inc(IMVT) | COM | 45258J102 | $14.6M | 853,472 | 4.6% |
| Madrigal Pharmaceuticals Inc(MDGL) | COM | 558868105 | $13.6M | 40,936 | 4.3% |
| Nuvalent Inc(NUVL) | COM | 670703107 | $13.5M | 190,401 | 4.3% |
| Revolution Medicines Inc(RVMD) | COM | 76155X100 | $11.3M | 318,782 | 3.6% |
| Janux Therapeutics Inc(JANX) | COM | 47103J105 | $9.2M | 342,062 | 2.9% |
| Xenon Pharmaceuticals Inc(XENE) | COM | 98420N105 | $9.2M | 274,633 | 2.9% |
| Denali Therapeutics Inc(DNLI) | COM | 24823R105 | $9.1M | 667,078 | 2.9% |
| Centessa Pharmaceuticals PLC(CNTA) | SPONSORED ADS | 152309100 | $8.5M | 593,335 | 2.7% |
| Uniqure NV(QURE) | SHS | N90064101 | $7.7M | 731,039 | 2.5% |
| Bridgebio Pharma Inc(BBIO) | COM | 10806X102 | $7.2M | 208,437 | 2.3% |
| CG Oncology Inc(CGON) | COM | 156944100 | $7.1M | 289,823 | 2.3% |
| Springworks Therapeutics Inc | COM | 85205L107 | $7.0M | 159,305 | 2.2% |
| Arcutis Biotherapeutics Inc(ARQT) | COM | 03969K108 | $6.9M | 440,073 | 2.2% |
| Insmed Inc(INSM) | COM PAR $.01 | 457669307 | $6.6M | 87,059 | 2.1% |
| Alkermes PLC(ALKS) | SHS | G01767105 | $6.4M | 192,352 | 2.0% |
| Akero Therapeutics Inc(AKRO) | COM | 00973Y108 | $6.3M | 156,185 | 2.0% |
| Biohaven LTD(BHVN) | COM | G1110E107 | $6.0M | 250,564 | 1.9% |
| Cytokinetics Inc(CYTK) | COM NEW | 23282W605 | $6.0M | 149,648 | 1.9% |
| Blueprint Medicines Corp(2L9) | COM | 09627Y109 | $5.5M | 61,927 | 1.7% |
| Vistagen Therapeutics Inc(VTGN) | COM | 92840H400 | $5.1M | 2,366,554 | 1.6% |
| Protara Therapeutics Inc(TARA) | COM STK | 74365U107 | $5.1M | 1,190,579 | 1.6% |
| Kalvista Pharmaceuticals Inc(KALV) | COM | 483497103 | $4.5M | 386,837 | 1.4% |
| Edgewise Therapeutics Inc(EWTX) | COM | 28036F105 | $4.0M | 180,255 | 1.3% |
| Surrozen Inc(SRZN) | COM NEW | 86889P208 | $2.8M | 240,826 | 0.9% |
| Protagonist Therapeutics Inc(PTGX) | COM | 74366E102 | $2.4M | 49,241 | 0.8% |
| Enliven Therapeutics Inc(ELVN) | COM | 29337E102 | $2.4M | 120,430 | 0.8% |
| Neurocrine Biosciences Inc(NBIX) | COM | 64125C109 | $2.3M | 21,052 | 0.7% |
| Ascendis Pharma A/S(ASND) | SPONSORED ADR | 04351P101 | $2.3M | 14,732 | 0.7% |
| Helix Acquisition Corp II | CL A ORD SHS | G4444H101 | $2.3M | 200,900 | 0.7% |
| Spyre Therapeutics Inc(SYRE) | COM NEW | 00773J202 | $2.2M | 136,139 | 0.7% |
| Amicus Therapeutics Inc(FOLD) | COM | 03152W109 | $2.2M | 268,919 | 0.7% |
| Newamsterdam Pharma Company(NAMS) | ORDINARY SHARES | N62509109 | $2.1M | 104,585 | 0.7% |
| Rhythm Pharmaceuticals Inc(RYTM) | COM | 76243J105 | $1.8M | 33,816 | 0.6% |
| Arbutus Biopharma Corp(ABUS) | COM | 03879J100 | $1.6M | 467,882 | 0.5% |
| Perceptive Cap Solutions COR | CL A ORD SHS | G70077105 | $1.5M | 150,000 | 0.5% |
| Geron Corp(GERN) | COM | 374163103 | $1.5M | 960,307 | 0.5% |
| Ideaya Biosciences Inc(IDYA) | COM | 45166A102 | $1.1M | 66,999 | 0.3% |
| ZAI LAB LTD(ZLAB) | ADR | 98887Q104 | $954.9K | 26,421 | 0.3% |
| Ocular Therapeutix Inc(OCUL) | COM | 67576A100 | $912.8K | 124,523 | 0.3% |
| Dyne Therapeutics Inc(DYN) | COM | 26818M108 | $883.1K | 84,430 | 0.3% |
| Soleno Therapeutics Inc(SLNO) | COM | 834203309 | $797.0K | 11,155 | 0.3% |
| Inflarx NV(IFRX) | COM | N44821101 | $739.5K | 725,019 | 0.2% |
| Solid Biosciences Inc(SLDB) | COM NEW | 83422E204 | $733.2K | 198,150 | 0.2% |
| Wave Life Sciences LTD(WVE) | SHS | Y95308105 | $725.9K | 89,833 | 0.2% |
| MBX Biosciences Inc(MBX) | COM | 55287L101 | $713.0K | 96,615 | 0.2% |